Equipped with advanced cognitive computing technologies, we are able to aggregate and mine disparate types of biomedical datasets to reveal novel contextual vulnerabilities in cancer, and collaborate with leading universities to exploit those vulnerabilities with cutting-edge agents.
We then invest in the most promising experimental agents to demonstrate their therapeutic potential. Finally, we partner with pharmaceutical companies to transform innovative new agents into the breakthrough cancer therapies.
Our approach to cancer research is revolutionary. Applying the exponential power of our cognitive computing platform and a unique multi-scalar systems modeling approach, our team of scientists are able to extract much deeper insights into the molecular contexts that represent the best therapeutic vulnerabilities in cancer. Modeling multi-dimensional disease mechanisms is critical to our ability to discover truly novel therapeutic opportunities. Understanding these mechanisms also allows us to resolve clinical heterogeneity in drug development. Taken together, this unique process empowers us to discover and develop the next generation of cancer therapies with unprecedented speed and precision.
In silico discovery research
Use in silico insights to predict and prioritize
In-licensing of top candidates
Invest in studies to demonstrate safety, efficacy & mechanism
Out-licensing of products
Industry Innovators with Deep Experience
Dr. Mousses is widely recognized as a leading scientist in the application of genomics, RNAi, systems biology, and machine learning to improve and accelerate cancer drug discovery and development. He has published more than 60 patents, scientific articles, and book chapters. He served as Director of the Pharmaceutical Genomics Division at the Translational Genomics Research Institute (TGen), where he led 8 laboratories to develop more than 30 programs and collaborated with pharmaceutical partners to accelerate cancer drug development. Prior to that, he served as Staff Scientist at the National Human Genome Research Institute (NHGRI), NIH, leading a program in cancer genome scanning and high throughput technology.
As a successful entrepreneur, Dr. Mousses has previously founded several biotech and IT companies, including Systems Medicine (acquired by Cell Therapeutics), MedTrust Online (acquired by Annai Systems), and Systems Imagination, which offers advanced cognitive computing technology to translate big data into biomedical insights.
Dr. Mousses received his PhD in Molecular Pathogenesis and Genetics of Cancer from the University of Toronto.
Language: English
Andrew has 20 years of private equity and healthcare industry experience. As Managing Partner of Lakeshore Capital Partners, Andrew is responsible for evaluating potential investment opportunities, structuring and executing transactions and portfolio company oversight. In his role at Lakeshore, Andrew also provides financial consulting and executive-level management services.
Prior to founding Lakeshore Capital Partners, Andrew worked in brand management at Amgen. While at Amgen, he took on increasing levels of responsibility in the sales and marketing organization. In his most recent role, he directed the strategic planning and operations function for a groundbreaking oncology product launch.
Previously, Andrew worked as an investment banking analyst for Credit Suisse First Boston, where he focused on mergers and acquisitions advisory and debt and equity financings.
Andrew holds a BA from the University of Michigan and an MBA from The Fuqua School of Business at Duke University, with a concentration in Health Sector Management.
Language: English
Lee has over 25 years of experience in the healthcare industry. He is a successful entrepreneur, having founded, acquired and run multiple companies; including Data Management, Inc. (acquired by MedData), On Point Technology, GrandStay Hospitality and Lakeshore Capital Partners.
Lee’s responsibilities have included executive operating roles, business development, sourcing and evaluating investment opportunities, structuring and executing transactions, portfolio company management, capital raising, and fund management.
Prior to co-founding Lakeshore Capital Partners, Lee spent 12 years at St. Jude Medical. In his most recent role as a Field Clinical Engineer, his responsibilities included designing, implementing, and managing clinical trials for next-generation Cardiac Rhythm Management products, including implantable cardioverter defibrillators (ICD), cardiac pacemakers, and delivery tools.
Lee is a named author on multiple scientific papers and is a graduate of Marquette University.
Language: English
Ron has had a distinguished career for the past five decades in the healthcare industry. From 1993 to 2002, he led St. Jude Medical, Inc. in roles of President, CEO, and Chairman. Prior to that, he spent 23 years at Eli Lilly and Company, serving in various roles including President of its pharmaceutical division in North America, Lilly International, and its medical device division. In addition, he served on the board of numerous public and private companies, including Home Depot, Life Technology, Kinetic Concepts, Phoenix Children’s Hospitals, as well as many others.
Ron is currently Chairman of the Board for Systems Oncology and Orthofix International N.V. He is also a Limited Partner at Lakeshore Capital Partners, LLC.
Ron holds a BS degree from Massachusetts College of Pharmacy, and was awarded an honorary Doctor degree in Pharmacy. He also earned a Life Time Achievement award for his significant contributions to the healthcare industry.
Language: English
Dr. Mousses is widely recognized as a leading scientist in the application of genomics, RNAi, systems biology, and machine learning to improve and accelerate cancer drug discovery and development. He has published more than 60 patents, scientific articles, and book chapters. He served as Director of the Pharmaceutical Genomics Division at the Translational Genomics Research Institute (TGen), where he led 8 laboratories to develop more than 30 programs and collaborated with pharmaceutical partners to accelerate cancer drug development. Prior to that, he served as Staff Scientist at the National Human Genome Research Institute (NHGRI), NIH, leading a program in cancer genome scanning and high throughput technology.
As a successful entrepreneur, Dr. Mousses has previously founded several biotech and IT companies, including Systems Medicine (acquired by Cell Therapeutics), MedTrust Online (acquired by Annai Systems), and Systems Imagination, which offers advanced cognitive computing technology to translate big data into biomedical insights.
Dr. Mousses received his PhD in Molecular Pathogenesis and Genetics of Cancer from the University of Toronto.
Language: English
Dr. Von Hoff has been instrumental in the development and approval of many life-saving cancer therapies including gemcitabine, fludarabine, paclitaxel, docetaxel, topotecan, irinotecan, mitoxantrone,vismodegib, nab-paclitaxel and others. He is currently Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Professor of Medicine at the Mayo Clinic, and the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at Honor Health Research Institute.
Dr. Von Hoff is a former member of the FDA’s Oncology Drug Advisory Committee (ODAC) and served on President Bush’s National Cancer Advisory Board. He was previously the Director of the Arizona Cancer Center and former president of the American Association of Cancer Research (AACR). He is a past member of the Board of Scientific Advisors of the National Cancer Institute, as well as a former board member of the American Society of Clinical Oncology (ASCO). Dr. Von Hoff co-founded ILEX Oncology, Inc. in 1993, which was later acquired by Genzyme Corp. in 2004 for $1 billion.
Dr. Von Hoff has published more than 730 papers, 141 book chapters and over 1165 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from ASCO for his outstanding contributions to cancer research leading to significant improvement in patient care. He has also edited the Cancer Chemotherapy Handbook and has had seats on the editorial board of 12 scientific journals, including the founding Editor-in-Chief of Molecular Cancer Therapeutics. Dr. Von Hoff is also currently the Team Leader for the Stand Up to Cancer (SU2C Sponsored) Dream Team focused on developing new agents targeting pancreatic cancer.
Language: English
Gavin has more than 20 years of global licensing and legal experience across sectors with an emphasis on cross-border business and intellectual property strategy issues. His experience includes corporate transactions, such as acquisitions, financings, licensing and divestitures, managing intellectual property holdings and devising intellectual property strategies. Gavin is a US patent attorney and a Canadian trademark agent. He has significant experience in life sciences law and licensing, including pharmaceutical, biotechnology, and nutritional supplement matters. Gavin has a JD, an MBA and an MS.
Gavin was General Counsel at Iovate, a mid-sized private Canadian company; Patent Counsel at Wyeth Pharmaceuticals in Cambridge MA; Senior Patent Attorney at Genetics Institute in Cambridge MA; and a patent attorney at a major New York IP firm. Gavin also held a clerkship at the Tax Court of Canada.
Language: English
Dr. Yoo has over 25 years of experience in advancing cutting-edge biomedical information technology. He is the founder and CEO of Systems Imagination, Inc., which offers advanced cognitive computing technology to translate big data into valuable insights. At IBM, he was instrumental as Head of Strategy and Planning for IBM’s Information Based Medicine business, a new unit that pioneered the infusion of high performance computing and research into the nascent fields of personalized medicine and molecular therapeutics based on genomics. Throughout his career, he has also held leadership positions at Cisco, Oracle, and Applied Biosystems.
As a serial entrepreneur, Dr. Yoo has created value in new companies that accelerate the adoption of smarter, technology-based systems such as cognitive computing, big data analytics, and knowledge engineering. He has founded and successfully engineered the exit of startups including MedTrust Online, the world’s first and largest online community of cancer doctors treating difficult cases with molecular medicine knowledge. He has also founded Golden Gateway Partners, a trans-Pacific technology consulting company, TransMed Partners, the first boutique consultancy for translational medicine, and LabBook, the first electronic laboratory notebook for HCLS researchers.
In addition to his leadership roles at Systems Oncology and Systems Imagination, Dr. Yoo is also a Faculty Associate in the College of Health Solutions at Arizona State University. Dr. Yoo received his PhD in Cell and Molecular Biology from Yale University, and completed his postdoctoral fellowship at UC Berkeley.
Language: English
Alex is Chairman and CEO of Tissue Differentiation intelligence (TDi). He is a serial entrepreneur and immediate past Chairman and CEO of NuVasive, Inc. (de facto founder). He has over 35 years of medical technology industry experience, serving as a senior executive at Medtronic Sofamor Danek, BackCare Group, Smith and Nephew Orthopedics, and a Meadox/Stryker joint venture. He is a long standing orthopedic industry expert, and has received multiple achievement awards in entrepreneurship and leadership, as well as many public appearances at conferences, panels, TV, media, and in Washington, DC.
Alex served on a variety of public, private and not for profit boards including California Health Institute, BIOCOM, Medical Device & Manufacturers Association, Volcano, etc. Currently, he is serving on the public company board of Orthofix, several private and not for profit boards including Chairman and CEO (co-founder) of TDi, Systems Oncology, OnPoint, Holy Trinity Seminary, Chairman of St Photios Orthodox Theological Seminary, and Chairman and CEO of Patriarch Tikhon Russian-American Music Institute.
Alex directs his focus largely on developing new businesses, investments, and proliferation of the arts. He studied at Rutgers, The State University of New Jersey.
Language: English
Dr. Von Hoff has been instrumental in the development and approval of many life-saving cancer therapies including gemcitabine, fludarabine, paclitaxel, docetaxel, topotecan, irinotecan, mitoxantrone,vismodegib, nab-paclitaxel and others. He is currently Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Professor of Medicine at the Mayo Clinic, and the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at Honor Health Research Institute.
Dr. Von Hoff is a former member of the FDA’s Oncology Drug Advisory Committee (ODAC) and served on President Bush’s National Cancer Advisory Board. He was previously the Director of the Arizona Cancer Center and former president of the American Association of Cancer Research (AACR). He is a past member of the Board of Scientific Advisors of the National Cancer Institute, as well as a former board member of the American Society of Clinical Oncology (ASCO). Dr. Von Hoff co-founded ILEX Oncology, Inc. in 1993, which was later acquired by Genzyme Corp. in 2004 for $1 billion.
Dr. Von Hoff has published more than 730 papers, 141 book chapters and over 1165 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from ASCO for his outstanding contributions to cancer research leading to significant improvement in patient care. He has also edited the Cancer Chemotherapy Handbook and has had seats on the editorial board of 12 scientific journals, including the founding Editor-in-Chief of Molecular Cancer Therapeutics. Dr. Von Hoff is also currently the Team Leader for the Stand Up to Cancer (SU2C Sponsored) Dream Team focused on developing new agents targeting pancreatic cancer.
Language: English
Professor Hergenrother’s research focuses on the design and evaluation of novel small molecules for the treatment of intractable diseases. He is the co-founder and Chief Scientific Officer of Vanquish Oncology, and an anticancer compound discovered by his lab is being evaluated in clinical trials in cancer patients.
Professor Hergenrother joined the faculty at the University of Illinois in 2001. At the University, he is the Leader of the Theme “Anticancer Discovery from Pets to People” at the Institute for Genomic Biology, and is the Director of the NIH Chemistry-Biology Interface Training Grant. He was the recipient of the 2016 Innovation Transfer Award from the University, was named as an American Cancer Society Research Scholar, and was named by Technology Review magazine as one of the top innovators under the age of 35. More recently, he was named as the recipient of the 2016 UCB-Ehrlich Award for Excellence in Medicinal Chemistry, a 2017 ACS Arthur C. Cope Scholar Award, and the 2018 ACS Sosnovsky Award for Cancer Research.
Professor Hergenrother received his PhD in Chemistry from the University of Texas at Austin, and completed an American Cancer Society Postdoctoral Fellowship at Harvard University.
Language: English
Dr. Mousses is widely recognized as a leading scientist in the application of genomics, RNAi, systems biology, and machine learning to improve and accelerate cancer drug discovery and development. He has published more than 60 patents, scientific articles, and book chapters. He served as Director of the Pharmaceutical Genomics Division at the Translational Genomics Research Institute (TGen), where he led 8 laboratories to develop more than 30 programs and collaborated with pharmaceutical partners to accelerate cancer drug development. Prior to that, he served as Staff Scientist at the National Human Genome Research Institute (NHGRI), NIH, leading a program in cancer genome scanning and high throughput technology.
As a successful entrepreneur, Dr. Mousses has previously founded several biotech and IT companies, including Systems Medicine (acquired by Cell Therapeutics), MedTrust Online (acquired by Annai Systems), and Systems Imagination, which offers advanced cognitive computing technology to translate big data into biomedical insights.
Dr. Mousses received his PhD in Molecular Pathogenesis and Genetics of Cancer from the University of Toronto.
Language: English
We welcome opportunities to collaborate with leading pharmaceutical companies to advance innovative multi-targeting therapies.
